Research programme: polo-like protein kinase inhibitors - AmgenAlternative Names: Plk-1 inhibitors -Amgen
Latest Information Update: 09 Sep 2008
At a glance
- Originator Amgen
- Mechanism of Action Polo-like kinase 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Apr 2006 Preclinical trials in Cancer in USA (unspecified route)